|
Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 18S ( Supplement), :
© 2009 American Society of Clinical Oncology
|
PCb plus C |
PCb followed by C |
|
|
N=106 |
N =119 |
| Response Rate |
26/71 (37%; 26%-49%) |
22/85 (26%; 17%-37%) |
| Disease Control Rate |
53/71 (75%; 63%-84%) |
60/85 (71%; 60%-80%) |
| Median PFS |
4.2 months (3.6–4.6) |
4.4 months (4.1–5.2) |
| Median survival |
10.5 months (7.1–10.5) |
8.7 months (7.2–9.9) |
| G 3/4 Neutropenia |
41% |
37% |
| G3/4 Febrile Neutropenia |
4% |
2% |
| G3/4 Rash |
12% |
5% |
| G3/4 Allergic rx |
5% |
1% |
|
|
